Moderna (MRNA) Other Operating Expenses (2017 - 2026)

Moderna (MRNA) has 9 years of Other Operating Expenses data on file, last reported at $955.0 million in Q1 2026.

• Other Operating Expenses for Q1 2026 came in at $955.0 million, up 961.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.7 billion (up 18.86% YoY), and the FY2025 annual result was $868.0 million, down 40.71% from the prior year.
• Other Operating Expenses rose to $955.0 million in Q1 2026 per MRNA's latest filing, from $452.0 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $2.2 billion in Q3 2023 and troughed at $90.0 million in Q1 2025.
• A 5-year average of $788.0 million and a median of $739.0 million in 2024 frame the typical range for Other Operating Expenses.
• The sharpest annual moves came in 2024 and 2026: Other Operating Expenses tumbled 87.88% in 2024, then soared 961.11% in 2026.
• A 5-year view of Other Operating Expenses shows it stood at $1.9 billion in 2022, then plunged by 51.56% to $929.0 million in 2023, then slipped by 20.45% to $739.0 million in 2024, then sank by 38.84% to $452.0 million in 2025, then soared by 111.28% to $955.0 million in 2026.
• Business Quant data shows MRNA's Other Operating Expenses at $955.0 million in Q1 2026, $452.0 million in Q4 2025, and $207.0 million in Q3 2025.